BCM
CTMX icon

Bridgeway Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Bridgeway Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-126,000
Closed -$286K – 1216
2025
Q2 		$286K Sell
126,000
-180,624
-59% -$291K 0.01% 876
2025
Q1 		$195K Sell
306,624
-25,000
-8% -$19.4K ﹤0.01% 933
2024
Q4 		$342K Sell
331,624
-25,000
-7% -$26.9K 0.01% 895
2024
Q3 		$421K Sell
356,624
-12,500
-3% -$15.9K 0.01% 902
2024
Q2 		$450K Sell
369,124
-74,100
-17% -$147K 0.01% 882
2024
Q1 		$966K Buy
443,224
+8,700
+2% +$16.1K 0.02% 751
2023
Q4 		$674K Buy
434,524
+62,400
+17% +$82K 0.01% 866
2023
Q3 		$480K Buy
372,124
+134,100
+56% +$211K 0.01% 884
2023
Q2 		$409K Buy
238,024
+62,024
+35% +$103K 0.01% 960
2023
Q1 		$266K Hold
176,000
– – 0.01% 1047
2022
Q4 		$282K Hold
176,000
– – 0.01% 1003
2022
Q3 		$255K Buy
+176,000
New +$271K 0.01% 1087

Other funds holding CTMX

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bridgeway Capital Management's CTMX Position: Q3 2025 in Review

Bridgeway Capital Management sold out of CytomX Therapeutics (CTMX) in Q3 2025, closing a stake of 126,000 shares — an estimated $286K sold.

Bridgeway Capital Management first reported a position in CTMX in Q3 2022 and held it in 12 quarters. The position peaked at $966K in Q1 2024. 103 funds tracked by Wall St. Rank hold CTMX as of Q3 2025.

  • Bridgeway Capital Management reported no remaining CytomX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 126,000 CytomX Therapeutics shares in Q3 2025, an estimated $286K.
  • Bridgeway Capital Management first reported a position in CytomX Therapeutics in Q3 2022 and held it in 12 quarters.
  • Bridgeway Capital Management's CytomX Therapeutics position peaked at $966K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2025.

Based on Bridgeway Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.